Healthcare / Drug Manufacturers - GeneralKOSDAQ
$2580.00
-105.00 (-3.91%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-1.5B · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$129.5B
P/E
N/A
•EV/EBITDA
35.4x
↑ROE
-4.5%
↓Gross Margin
14.1%
↓Debt/Equity
0.48
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+8.1%
FCF CAGR
—
FCF margin
5.7%
FCF / Net income
-1.73x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $131.04B · net income $-4.30B · FCF $7.42B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $131.04B | $131.04B | $136.47B | $122.00B | $103.71B |
| Net Income | $-4.30B | $-4.30B | $1.74B | $4.82B | $8.95B |
| EBITDA | $4.72B | $4.72B | $14.20B | $10.61B | $14.33B |
| EPS | -86.00 | -86.00 | 35.00 | 98.00 | 182.00 |
| Gross Margin | 14.1% | 14.1% | 16.0% | 20.7% | 18.8% |
| Operating Margin | -2.0% | -2.0% | 0.3% | 5.3% | 3.4% |
| Net Margin | -3.3% | -3.3% | 1.3% | 4.0% | 8.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.48 | 0.48 | 0.67 | 0.82 | 0.65 |
| Current Ratio | 1.32 | 1.32 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $7.42B | $7.42B | $-1.52B | $-38.37B | $-29.79B |
| Returns | |||||
| ROE | -4.5% | -4.5% | 1.8% | 5.0% | 9.8% |
| Valuation | |||||
| P/E | — | — | 104.14 | 64.49 | 36.37 |
| EV/EBITDA | 35.41 | 35.41 | 14.03 | 35.72 | 25.34 |
| P/B | 1.34 | 1.34 | 1.86 | 3.23 | 3.55 |
| Growth & Yield | |||||
| Revenue Growth | -4.0% | -4.0% | 11.9% | 17.6% | — |
| EPS Growth | -345.7% | -345.7% | -64.3% | -46.2% | — |
| Dividend Yield | 0.3% | 0.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-14.8%
Start / end P/E
n/dx → n/dx
EPS bridge
35.00 → -86.00
Residual
-15.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.